Breaking News, Financial News

Financial Report: Biogen Idec 3Q

Avonex revenues increased 11% to $644 million in the quarter and Tysabri revenues were up 7% to $221 million.

Biogen Idec 3Q

3Q Revenues: $1.2 billion (+5%)

3Q Earnings: $254 million (-8%)

YTD Revenues:
$3.5 billion (+8%)

YTD Earnings: $765.0 million (+15%)

Comments:
Avonex revenues increased 11% to $644 million in the quarter and Tysabri revenues were up 7% to $221 million. Rituxan revenues were down 9% to $258 million. Royalty revenues were $36 million in the quarter (+3%). Biogen sells Tysabri through a partnership with Elan Corp. and markets Rituxan with Roche’s Genentech division.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters